Korean Market
EXCH
Samsung Pharmaceutical
★

Samsung Pharmaceutical discloses corporate governance report: only 4 out of 15 core indicators met, lack of shareholder return and CEO succession policy highlights need for governance improvement

 
PERI
Samsung Pharmaceutical
★

Samsung Pharm Q1 2026: Net Income Plunges but PSP Conditional Approval Filed and Lawsuits Resolved

 
EXCH
Samsung Pharmaceutical
★★★★

Lawsuit for Damages Against Biovill Withdrawn by Plaintiff